Preliminary data from a Phase II trial of Clovis Oncology’s Rubraca (rucaparib) for maintenance of advanced BRCA- or PALB2-related pancreatic...
Read More...
The post PARP inhibitors make inroads in pancreatic cancer appeared first on Pharmaceutical Technology.
Original Article: PARP inhibitors make inroads in pancreatic cancer